Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 6, 2016

AstraZeneca and Foundation Medicine to develop new companion diagnostic assay

UK-based AstraZeneca has signed an agreement with US-based Foundation Medicine to develop a new diagnostic assay for Lynparza (olaparib).

UK-based AstraZeneca has signed an agreement with US-based Foundation Medicine to develop a new diagnostic assay for Lynparza (olaparib).

Lynparza is an orally administered poly ADP-ribose polymerase (PARP) inhibitor that leverages on tumour DNA repair pathway deficiencies to eliminate cancer cells.

Under the deal, Foundation Medicine will develop a regulatory approved product based on its quality systems regulations (QSR) compliant version of FoundationOne comprehensive genomic profiling platform.

"This agreement supports the broad development programme for our first-in-class PARP inhibitor, Lynparza."

A multiple class of genomic alterations across a range of genes involved in homologous recombination repair (HRR) will be detected by the new assay, which is based on a scientifically selected panel of genes involved in driving the HRR process.

AstraZeneca Lynparza global medicine lead Nina Mojas said: "This agreement supports the broad development programme for our first-in-class PARP inhibitor, Lynparza.

"Utilising Foundation Medicine’s leading capabilities in molecular information will help our work to assess the potential of the medicine to address unmet patient need across a number of cancers driven by DNA repair deficiencies, including and significantly beyond the BRCA mutations."

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The assay will be developed in conjunction with the clinical programme for Lynparza, as a part of a coordinated drug-diagnostic regulatory strategy.

The companion diagnostic assay will assist physicians to determine the specific patients who will be benefitted from AstraZeneca’s PARP inhibitor, Lynparza.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU